Steven Lichtman
Stock Analyst at Oppenheimer
(2.88)
# 1,497
Out of 5,169 analysts
72
Total ratings
38.46%
Success rate
10.85%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steven Lichtman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNDM Tandem Diabetes Care | Maintains: Outperform | $44 → $22 | $23.85 | -7.76% | 2 | Sep 8, 2025 | |
| PODD Insulet | Maintains: Outperform | $324 → $365 | $230.28 | +58.50% | 8 | Sep 8, 2025 | |
| BSX Boston Scientific | Upgrades: Outperform | $118 → $125 | $71.28 | +75.36% | 4 | Sep 8, 2025 | |
| DXCM DexCom | Maintains: Outperform | $95 → $102 | $67.66 | +50.75% | 9 | Jul 31, 2025 | |
| ZBH Zimmer Biomet Holdings | Maintains: Outperform | $145 → $135 | $89.08 | +51.55% | 7 | Oct 15, 2024 | |
| MNKD MannKind | Maintains: Outperform | $10 → $12 | $2.61 | +359.77% | 2 | Aug 28, 2024 | |
| ALC Alcon | Maintains: Outperform | $103 → $110 | $75.74 | +45.23% | 3 | Aug 22, 2024 | |
| MDT Medtronic | Maintains: Perform | $92 → $94 | $87.21 | +7.79% | 10 | Aug 21, 2024 | |
| RXST RxSight | Maintains: Outperform | $72 → $65 | $7.35 | +784.35% | 8 | Aug 6, 2024 | |
| BWAY BrainsWay | Maintains: Outperform | $5 → $5.5 | $13.44 | -59.08% | 5 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $12 | $10.40 | +15.38% | 2 | Apr 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $82 → $87 | $68.27 | +27.44% | 1 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $3.5 | $0.22 | +1,514.39% | 2 | Sep 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $273 → $288 | $345.81 | -16.72% | 2 | Jul 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $105 | $103.22 | +1.72% | 3 | Jul 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | $150 | $18.58 | +707.32% | 1 | Jul 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $83 → $85 | $71.17 | +19.43% | 3 | Sep 4, 2020 |
Tandem Diabetes Care
Sep 8, 2025
Maintains: Outperform
Price Target: $44 → $22
Current: $23.85
Upside: -7.76%
Insulet
Sep 8, 2025
Maintains: Outperform
Price Target: $324 → $365
Current: $230.28
Upside: +58.50%
Boston Scientific
Sep 8, 2025
Upgrades: Outperform
Price Target: $118 → $125
Current: $71.28
Upside: +75.36%
DexCom
Jul 31, 2025
Maintains: Outperform
Price Target: $95 → $102
Current: $67.66
Upside: +50.75%
Zimmer Biomet Holdings
Oct 15, 2024
Maintains: Outperform
Price Target: $145 → $135
Current: $89.08
Upside: +51.55%
MannKind
Aug 28, 2024
Maintains: Outperform
Price Target: $10 → $12
Current: $2.61
Upside: +359.77%
Alcon
Aug 22, 2024
Maintains: Outperform
Price Target: $103 → $110
Current: $75.74
Upside: +45.23%
Medtronic
Aug 21, 2024
Maintains: Perform
Price Target: $92 → $94
Current: $87.21
Upside: +7.79%
RxSight
Aug 6, 2024
Maintains: Outperform
Price Target: $72 → $65
Current: $7.35
Upside: +784.35%
BrainsWay
May 9, 2024
Maintains: Outperform
Price Target: $5 → $5.5
Current: $13.44
Upside: -59.08%
Apr 5, 2024
Upgrades: Outperform
Price Target: $12
Current: $10.40
Upside: +15.38%
Feb 29, 2024
Maintains: Outperform
Price Target: $82 → $87
Current: $68.27
Upside: +27.44%
Sep 19, 2023
Reiterates: Outperform
Price Target: $3.5
Current: $0.22
Upside: +1,514.39%
Jul 28, 2021
Maintains: Perform
Price Target: $273 → $288
Current: $345.81
Upside: -16.72%
Jul 14, 2021
Downgrades: Perform
Price Target: $105
Current: $103.22
Upside: +1.72%
Jul 9, 2021
Initiates: Perform
Price Target: $150
Current: $18.58
Upside: +707.32%
Sep 4, 2020
Maintains: Perform
Price Target: $83 → $85
Current: $71.17
Upside: +19.43%